The AlphaLISA® immunoassay kit for human PD-L2 enables the quantitative determination of human programmed death 1 ligand 2 (PD-L2) in serum and over-expressing cell lysates using a homogeneous AlphaLISA assay (no wash steps).
Item(s) added to cart.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Programmed Cell Death 1 Ligand 2 (PD-L2), also known as cluster of differentiation 273 (CD273) or B7-DC, is one of 2 ligands that binds to programmed death 1 (PD-1), the other being programmed cell death ligand 1 (PD-L1). These two ligands are members of the B7 superfamily that provide signals for regulating T-cell activation and tolerance. PD-L2 is expressed on a subset of dendritic cells, memory B cells, and monocytes in tissues, where its highest expression has been proven to be on the liver, heart, placenta, spleen, pancreas, and lymph node. The binding of PD-L2 and PD-1 promotes IFN-gamma production and CD40 ligand up-regulation while inhibiting IL-4 production.
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 Assay Points|